ZAGREB, Sept 7 (Hina) - In the first six months of 2000 Croatia's leading pharmaceutical company Pliva realised a net profit of 483.8 million kuna, which is a 28.2 percent increase in relation to 1999. Pliva's overall income amounted
to 2.5 billion kuna, which is a 28 percent increase. Of this amount, as much as 68.1 percent was realised on the international market, where the company's income has increased by as much as 44.7 percent to 1.7 billion kuna, Pliva's director and chairman of the management board, Zeljko Covic, told a news conference on Thursday. The sale of the company's best selling product, azithromicin, has increased by 132.9 percent to 482.7 million kuna in relation to the same period last year. The sale of Sumamed picked up as well, amounting to 135.9 million kuna. Covic announced that Pliva would focus its activities on the field of pharmacy and research an
ZAGREB, Sept 7 (Hina) - In the first six months of 2000 Croatia's
leading pharmaceutical company Pliva realised a net profit of 483.8
million kuna, which is a 28.2 percent increase in relation to 1999.
Pliva's overall income amounted to 2.5 billion kuna, which is a 28
percent increase. Of this amount, as much as 68.1 percent was
realised on the international market, where the company's income
has increased by as much as 44.7 percent to 1.7 billion kuna,
Pliva's director and chairman of the management board, Zeljko
Covic, told a news conference on Thursday.
The sale of the company's best selling product, azithromicin, has
increased by 132.9 percent to 482.7 million kuna in relation to the
same period last year. The sale of Sumamed picked up as well,
amounting to 135.9 million kuna.
Covic announced that Pliva would focus its activities on the field
of pharmacy and research and development. Investments into
research and development should by the end of this year amount to
320 million kuna, he said.
The company's Supervisory Board today elected Covic chairman of the
Management Board for a period of five years.
(hina) rml